Attendee search 

Yngzijiang Pharmaceutial Group is an integrated healthcare company in china, our business scope ranges from Pharma(small molcules,biological and TCM), Medical Device and consumer health products. With nearly 20000 employees around the world. We are the biggest private Pharmaceutial company by revenue in China, with a strong revenue growth rate in the past decade. We are open to any coopearation opportunities globally. Welcome to talk to us.

TRACTIVUS is a company derived from the research group GEMAT (IQS-Ramón Llull University) and IDIBELL (Bellvitge Biomedical Research Institute), located in Barcelona. We are an innovative company with expertise in antibacterial coatings, easy to be implemented on a wide range of medical devices.

PHOBOSTech™ technology have been developed over the years in Tractivus SL as a solution to the current problems of medical devices. Our cost-effective patented technology allows to create nanostructures on the surface, preventing bacteria attachment and, therefore, bacteria colonization. As a result our devices show higher lifetime, lower associated costs, and no post-implantation problems without adverse effect on the patients.

Tractivus SL combines the experience of the research groups and a unique solution designed to root out the colonization of the devices through a micro- and nano-structured coating that protects the device from adhesion and bacterial colonization. The team has worked on all aspects of the development: material selection, regulatory strategy, risk reduction, clinical trials, partners, stakeholders... aiming to maximize the success of both the project and the investors.

Digital physician platform for over 2.5 million registered Chinese doctors. We also help US pharma, biotech and medical device companies strategize and promote products and services directly to Chinese physicians.

The Research Institute of Tsinghua University in Shenzhen (RITS) was founded in 1996. RITS strives to establish an innovation incubation system and an industrial investment platform open to both China and abroad, cultivating strategic emerging industries.

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

maintect GmbH was founded 2018 in collaboration with Mainz University Medical Center Germany by ophthalmological scientists.
maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don’t benefit from anti-VEGF treatment and all others. maintect applied already for patent in several countries. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment and will facilitate the market entrance. Furthermore, the company is interested in contract research and collaborations in building diagnostic kits.

Avanc Pharmaceutical Co., Ltd (Avanc Pharma or the Company), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, focuses on innovative drug R&D, production and distribution and has a long-term commitment to nervous system, oncology, perioperative drugs and pediatric drugs.

Opera CRO is an international contract research organization (CRO) with offices in Italy (Genoa), in Switzerland (Geneva) and in Romania (Timisoara) that has been managing clinical trials since 1995. In particular, we performed several clinical studies with medical devices, medical drugs and food supplements in many different therapeutic areas.

We offer the possibility of conducting clinical trials in different countries in Eastern Europe, with reduced costs and faster times, or in other European and non-European countries (Italy, France, Switzerland, Germany etc..). Additionally, we offer specific support for the compliance of medical device registrations of the CE marking to the new European regulation. Recently, Opera CRO was acquired by the Tigermed group, the largest CRO in Asia with over 5000 employees and 100 offices. This partnership offers the opportunity to perform clinical trials in China and in the rest of Asia and access that vast market.
The list of our current studies can be found on ClinicalTrial.gov (specifying Opera CRO for Europe, Tigermed for Asia); further information is available on our website: www.operacro.com.